Nabriva Therapeutics (FRA:NTY) 3-Year Book Growth Rate : -78.90% (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Nabriva Therapeutics 3-Year Book Growth Rate?

Nabriva Therapeutics's Book Value per Share for the quarter that ended in Jun. 2023 was €-4.71.

During the past 12 months, Nabriva Therapeutics's average Book Value per Share Growth Rate was -137.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was -78.90% per year. During the past 5 years, the average Book Value per Share Growth Rate was -67.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 10 years, the highest 3-Year average Book Value per Share Growth Rate of Nabriva Therapeutics was 70.80% per year. The lowest was -78.90% per year. And the median was -54.90% per year.

Competitive Comparison of Nabriva Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Nabriva Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nabriva Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's 3-Year Book Growth Rate falls into.

Nabriva Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Nabriva Therapeutics (FRA:NTY) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Nabriva Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Nabriva Therapeutics (FRA:NTY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (FRA:NTY) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

NBRVF:USA

Address

Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website

https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Nabriva Therapeutics (FRA:NTY) Headlines

No Headlines